About
Bladder Cancer Treatment
Areas of Focus
Categories
Midwest
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
58
By Phase
PHASE1/PHASE2: 1PHASE2: 1PHASE1: 2
By Status
COMPLETED: 3TERMINATED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
Today
Hover over trial bars to see details
Recent Trials
NCT04956042Lead Sponsor
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
PHASE1/PHASE2Terminated
18 participants
Started: Aug 27, 2021 · Completed: Dec 31, 2023
NCT04525131Lead Sponsor
Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors
PHASE2Completed
12 participants
Started: Nov 25, 2020 · Completed: Jun 30, 2023
NCT04608045Lead Sponsor
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
PHASE1Completed
9 participants
Started: May 19, 2019 · Completed: Apr 30, 2023
NCT03348514Lead Sponsor
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
PHASE1Completed
19 participants
Started: Jan 15, 2018 · Completed: May 31, 2020
Locations (1)
Headquarters
Kansas City, MO, United States
Map
Loading map...